Peter C. Gøtzsche

Peter C. Gøtzsche's AcademicInfluence.com Rankings

Peter C. Gøtzsche

Philosophy

#1868

World Rank

#3303

Historical Rank

Logic

#428

World Rank

#814

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Peter C. Gøtzsche's Degrees

Doctorate Medicine University of Copenhagen
Masters Biostatistics University of Copenhagen

Why Is Peter C. Gøtzsche Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Peter Christian Gøtzsche is a Danish physician, medical researcher, and former leader of the Nordic Cochrane Center at Rigshospitalet in Copenhagen, Denmark. He is a co-founder of the Cochrane Collaboration and has written numerous reviews for the organization. His membership in Cochrane was terminated by its Governing Board of Trustees on 25 September 2018.

(See a Problem?)

Peter C. Gøtzsche's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials (2011) (21564)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration (2009) (20340)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. (2007) (18663)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration (2009) (13688)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. (2009) (7631)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies (2007) (7183)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies (2007) (6009)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. (2008) (5931)
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (2010) (4153)
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007) (4141)
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration (2001) (3830)
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (2010) (3790)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. (2014) (3753)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations (2015) (3720)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. (2009) (3700)
SPIRIT 2013 statement: defining standard protocol items for clinical trials. (2013) (3679)
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials (2013) (3035)
Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies (2007) (2358)
CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. (2010) (2066)
[The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. (2007) (1810)
Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. (2004) (1706)
Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. (2001) (1468)
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007) (1422)
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. (2007) (1310)
Explanation and Elaboration (1282)
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. (2007) (1260)
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement (2004) (1135)
Screening for breast cancer with mammography. (2013) (984)
Guidelines for Reporting Observational Studies (2007) (892)
Is screening for breast cancer with mammography justifiable? (2000) (849)
Cochrane review on screening for breast cancer with mammography (2001) (761)
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. (2008) (688)
SPIRIT 2013 Statement: defining standard protocol items for clinical trials. (2015) (688)
Increasing value and reducing waste: addressing inaccessible research (2014) (667)
[The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. (2007) (581)
Placebo interventions for all clinical conditions. (2004) (520)
Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends (2009) (509)
PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts (2013) (449)
Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review (2006) (444)
Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. (2007) (442)
Erratum to: “CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials” [J Clin Epidemiol 2010;63(8):e1–37] (2012) (412)
Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention (2009) (376)
Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups (2009) (373)
Non-steroidal anti-inflammatory drugs (2000) (369)
Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment (2004) (356)
Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. (1989) (343)
Alpha1-antitrypsin deficiency. (2009) (334)
A proposal for structured reporting of randomized controlled trials. The Standards of Reporting Trials Group. (1994) (299)
Meta-analysis of resting metabolic rate in formerly obese subjects. (1999) (296)
General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis (2012) (287)
Regular self-examination or clinical examination for early detection of breast cancer. (2003) (271)
Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports (2016) (261)
Declaración de la Iniciativa STROBE (Strengthening the Reporting of Observational studies in Epidemiology): directrices para la comunicación de estudios observacionales (2008) (256)
Ghost Authorship in Industry-Initiated Randomised Trials (2007) (254)
Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies (2008) (251)
Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review (2010) (235)
[Better reporting of harms in randomized trials: an extension of the CONSORT statement]. (2005) (229)
Reference bias in reports of drug trials. (1987) (224)
Prevalence of honorary and ghost authorship in Cochrane reviews. (2002) (224)
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2009) (222)
House dust mite control measures in the management of asthma: meta-analysis (1998) (221)
General health checks in adults for reducing morbidity and mortality from disease. (2012) (215)
Breast cancer mortality in organised mammography screening in Denmark: comparative study (2010) (213)
Placebo interventions for all clinical conditions. (2010) (209)
Data extraction errors in meta-analyses that use standardized mean differences. (2007) (191)
Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols (2008) (178)
Defective natural immunity: an early manifestation of human immunodeficiency virus infection (1995) (176)
Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study (2005) (172)
Breast screening: the facts—or maybe not (2009) (170)
House dust mite control measures for asthma. (2000) (168)
House dust mite control measures for asthma: systematic review (2008) (167)
Is there logic in the placebo? (1994) (159)
Quality of Cochrane reviews: assessment of sample from 1998 (2001) (158)
Content of invitations for publicly funded screening mammography (2006) (147)
Why we need a broad perspective on meta-analysis (2000) (146)
Deadly Medicines and Organised Crime (2013) (134)
Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study (2004) (132)
Mejorar la comunicación de estudios observacionales en epidemiología (STROBE): explicación y elaboración (2009) (132)
Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. (2004) (130)
Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? (2011) (128)
Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study (2011) (128)
Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. (1999) (122)
Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study (2010) (121)
Why we need easy access to all data from all clinical trials and how to accomplish it (2011) (120)
Blinding during data analysis and writing of manuscripts. (1996) (119)
House dust mite control measures for asthma. (2001) (116)
Opening up data at the European Medicines Agency (2011) (114)
Physical activity for secondary prevention of disease. Systematic reviews of randomised clinical trials. (2005) (113)
Lessons from and cautions about noninferiority and equivalence randomized trials. (2006) (109)
House dust mite control measures for asthma. (2008) (104)
Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis (1998) (103)
[The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. (2008) (103)
Mammographic screening: no reliable supporting evidence? (2002) (102)
Beware of Surrogate Outcome Measures (1996) (101)
Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia (1997) (101)
Laser and photoepilation for unwanted hair growth. (2006) (100)
Overdiagnosis in organised mammography screening in Denmark. A comparative study (2009) (99)
Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. (2011) (98)
What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. (2012) (95)
Multiple publication of reports of drug trials (2004) (92)
Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis (2013) (90)
Mammographic screening for breast cancer. (2003) (89)
What Should Be Done To Tackle Ghostwriting in the Medical Literature? (2009) (88)
Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: A marker of therapeutic success?—A 30‐year Cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection (2004) (85)
Somatostatin analogues for acute bleeding oesophageal varices. (2008) (85)
Believability of relative risks and odds ratios in abstracts: cross sectional study (2006) (85)
Constraints on publication rights in industry-initiated clinical trials. (2006) (85)
Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study (2013) (84)
Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis (1995) (81)
Das Strengthening the Reporting of Observational Studies in Epidemiology (STROBE-) Statement (2008) (80)
Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions (2008) (79)
Rational Diagnosis and Treatment: Evidence-Based Clinical Decision-Making (2000) (79)
Why mammography screening has not lived up to expectations from the randomised trials (2011) (77)
Declaración SPIRIT 2013: definición de los elementos estándares del protocolo de un ensayo clínico* (2015) (72)
Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. (2016) (72)
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. (2000) (72)
Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? (2012) (71)
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. (2007) (68)
Das Strengthening the Reporting of Observational Studies in Epidemiology (STROBE-) Statement (2008) (68)
Does long term use of psychiatric drugs cause more harm than good? (2015) (67)
Antidepressant Drug Effects and Depression Severity: A (2010) (67)
On the benefits and harms of screening for breast cancer. (2004) (64)
Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. (2004) (64)
Mammography screening: truth, lies, and controversy (2012) (63)
Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications (2014) (63)
Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study (2009) (61)
Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports (2017) (61)
Of mites and men: reference bias in narrative review articles: a systematic review. (2005) (60)
The benefits and harms of screening for cancer with a focus on breast screening. (2010) (58)
Breast Cancer Screening in Denmark (2017) (56)
Deadly Psychiatry and Organised Denial (2015) (56)
Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis (2016) (54)
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. (2005) (54)
General health checks in adults for reducing morbidity and mortality from disease. (2013) (54)
The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias (2018) (53)
Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data (2011) (53)
Storytelling as a method for teaching values and attitudes (1992) (53)
Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. (1997) (52)
House dust mite control measures for asthma. (2001) (52)
Teaching professionalism: passing the torch (1998) (51)
“Adaptive pathways” to drug authorisation: adapting to industry? (2016) (51)
General health checks in adults for reducing morbidity and mortality from disease. (2012) (51)
Challenges in Coding Adverse Events in Clinical Trials: A Systematic Review (2012) (50)
Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. (2009) (50)
Screening for reducing morbidity and mortality in malignant melanoma. (2016) (50)
The Breast Screening Programme and misinforming the public (2011) (49)
Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study (2010) (49)
Voriconazole versus amphotericin B in cancer patients with neutropenia. (2006) (48)
Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. (2008) (48)
Informed choice requires information about both benefits and harms (2009) (48)
Registries and registration of clinical trials. (2005) (48)
Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. (2006) (48)
Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study (2007) (47)
Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review (2017) (46)
Placebo treatment versus no treatment. (2002) (46)
Sponsors’ participation in conduct and reporting of industry trials: a descriptive study (2012) (46)
Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. (1990) (45)
Searching for unpublished data for Cochrane reviews: cross sectional study (2013) (43)
Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors (2018) (43)
Time to stop mammography screening? (2011) (43)
Nystatin prophylaxis and treatment in severely immunodepressed patients. (2014) (41)
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. (1998) (40)
Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers (2016) (39)
General health checks don’t work (2014) (38)
Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study (2011) (37)
[Double-blind dose-response study of zidovudine in AIDS and advanced HIV infection. Nordic Medical Research Councils' HIV Therapy Group]. (1993) (36)
Double-Blind Study of Naproxen vs Placebo in the Treatment of Acute Migraine Attacks (1989) (36)
The Journal Impact Factor as a Predictor of Trial Quality and Outcomes: Cohort Study of Hepatobiliary Randomized Clinical Trials (2005) (36)
Under-reporting of conflicts of interest among trialists: a cross-sectional study (2015) (34)
Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine (1988) (34)
Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study (1998) (34)
Trends in survival of Danish AIDS patients from 1981 to 1989. (1990) (34)
Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden (2006) (33)
Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. (2011) (33)
Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. (2014) (33)
PATIENTS' PREFERENCE IN INDOMETHACIN TRIALS: AN OVERVIEW (1989) (33)
Niels Finsen's treatment for lupus vulgaris (2011) (32)
Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. (1996) (32)
Mammography screening is harmful and should be abandoned (2015) (32)
Flawed inferences about screening mammography's benefit based on observational data. (2009) (32)
Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. (2000) (31)
Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review. (2007) (31)
Nystatin prophylaxis and treatment in severely immunodepressed patients. (2002) (30)
Condoms to prevent HIV transmission do not imply truly safe sex. (1988) (29)
Access to data in industry-sponsored trials (2011) (29)
Strengthening and opening up health research by sharing our raw data. (2012) (29)
Effect of screening mammography on breast cancer incidence. (2013) (28)
Screening with urinary dipsticks for reducing morbidity and mortality. (2015) (28)
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. (2007) (28)
Why I think antidepressants cause more harm than good. (2014) (27)
Big pharma often commits corporate crime, and this must be stopped (2012) (27)
Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. (1992) (26)
Adequacy of authors’ replies to criticism raised in electronic letters to the editor: cohort study (2010) (26)
Clinical guidelines on antidepressant withdrawal urgently need updating (2019) (26)
Comparison of Results from Different Imputation Techniques for Missing Data from an Anti-Obesity Drug Trial (2014) (25)
Routine versus selective antifungal administration for control of fungal infections in patients with cancer. (2000) (25)
Somatostatin analogues for acute bleeding oesophageal varices. (2005) (25)
Somatostatin analogues for acute bleeding oesophageal varices. (2002) (24)
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. (2002) (24)
The scientific basis of generalist medicine (1992) (24)
Comparison of search strategies for recalling double-blind trials from MEDLINE. (1991) (24)
Strategies for obtaining unpublished drug trial data: a qualitative interview study (2013) (24)
Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. (1989) (23)
The benefits and harms of breast cancer screening (2013) (23)
Citations of scientific results and conflicts of interest: the case of mammography screening (2013) (23)
Cimetidine suspension as adjuvant to energy restricted diet in treating obesity. (1993) (23)
Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. (1993) (23)
Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review (2018) (23)
Lead-Time Models Should Not Be Used to Estimate Overdiagnosis in Cancer Screening (2014) (21)
Should journals stop publishing research funded by the drug industry? (2014) (21)
Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. (2010) (21)
Breast Cancer Screening. International Agency for Research on Cancer (IARC) Handbooks of Cancer Prevention. Vol. 7. Harri Vainio and Franca Bianchini (eds). Lyon: IARC Press, 2002, pp. 229, Euro 40.00. ISBN: 92-832-3007-8 (2003) (21)
The Contribution of Handsearching European General Health Care Journals to the Cochrane Controlled Trials Register (2002) (21)
An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. (2011) (21)
A double-blind, randomized study of naproxen and acetylsalicylic acid after surgical removal of impacted lower third molars. (1986) (21)
Estimation of lead time and overdiagnosis in breast cancer screening (2009) (20)
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. (2014) (20)
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta- analysis (2009) (20)
Review of dose-response studies of NSAIDs in rheumatoid arthritis. (1989) (20)
Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis (2001) (20)
Changes in medical education: the community perspective (1996) (19)
The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder (2017) (19)
Routine versus selective antifungal administration for control of fungal infections in patients with cancer. (2014) (18)
Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. (2014) (18)
Steroids and peptic ulcer: an end to the controversy? (1994) (18)
Screening for breast cancer with mammography. (2011) (18)
Increased circulating levels of interleukin-6 in HIV-seropositive subjects. (1996) (18)
Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. (2006) (18)
More on screening mammography. (2011) (18)
Sample size of randomized double-blind trials 1976-1991. (1996) (18)
Unreliable analysis of placebo analgesia in trials of placebo pain mechanisms (2003) (18)
Universal health checks should be abandoned (2013) (18)
Opportunistic infections and malignancies in 231 Danish AIDS patients (1990) (18)
Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. (2010) (17)
Who evaluates public health programmes? A review of the NHS Breast Screening Programme (2010) (17)
Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations (2006) (17)
Concept of placebo should be discarded (1995) (17)
Declaración de la Iniciativa STOBE (Strengthening the Reporting of Observational Studies in Epidemiology): directrices para informar sobre los estudios observacionales (2007) (17)
Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports (2020) (16)
Our prescription drugs kill us in large numbers. (2014) (16)
Still awaiting screening facts (2010) (16)
Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. (2015) (15)
The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials. (2017) (15)
Deficiencies in proposed new EU regulation of clinical trials (2012) (15)
Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies. (2016) (15)
Trials of homoeopathy (1993) (15)
Isolation of HIV from cultures of purified CD4+ lymphocytes. (1991) (14)
Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis.. (2013) (14)
Somatostatin or octreotide for acute bleeding oesophageal varices. (2000) (14)
The debate on breast cancer screening with mammography is important. (2004) (14)
Screening for breast cancer with mammography (2001) (14)
Bias in double-blind trials. (1990) (13)
Observer variation in measurements of waist-hip ratio and the abdominal sagittal diameter. (1993) (13)
Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults (2017) (13)
[Constraints on publication rights in industry-initiated clinical trials--secondary publication]. (2006) (13)
Challenges of independent assessment of potential harms of HPV vaccines (2018) (13)
Regular Health Checks: Cross-Sectional Survey (2012) (12)
Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy. (1992) (12)
Breast screening: why estimates differ by a factor of 20-25 (2010) (12)
Research integrity and pharmaceutical industry sponsorship (2005) (11)
Biases in estimates of overdetection due to mammography screening. (2008) (11)
Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study (2014) (11)
Divine intervention? A Cochrane review on intercessory prayer gone beyond science and reason (2009) (11)
Screening mammography re-evaluated (2000) (10)
We need access to all data from all clinical trials. (2011) (10)
Ramifications of screening for breast cancer: Overdiagnosis in the Malmö trial was considerably underestimated (2006) (10)
Decreased Short-Term Production of Tumor Necrosis Factor-α and Interleukin-1β in Human Immunodeficiency Virus-Seropositive Subjects (1997) (10)
Bioavailability of naproxen tablets and suppositories in steady state. (1983) (10)
Presentation of benefits and harms of antidepressants on websites: A cross-sectional study (2020) (9)
Breast Cancer Screening: Benefit or Harm? (2016) (9)
Screening for colorectal cancer (1997) (9)
Non-steroidal anti-inflammatory drugs. (2002) (9)
Rationel Klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger (1997) (9)
Commentary: Screening: a seductive paradigm that has generally failed us. (2015) (9)
Misleading statements in industry-sponsored meta-analysis of itraconazole. (2005) (9)
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. (2001) (9)
Readers as research detectives (2009) (8)
Rational choice of dose: insufficient background knowledge? (1986) (8)
Patients not patents: Drug research and development as a public enterprise (2018) (8)
Minimal clinically important differences in chronic pain (2012) (8)
Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports. (2019) (8)
Re: Trends in the treatment of ductal carcinoma in situ of the breast. (2004) (8)
House dust mite control measures for asthma. (2004) (8)
Routine versus selective antifungal administration for control of fungal infections in patients with cancer. (2000) (8)
Nystatin prophylaxis and treatment in severely immunodepressed patients. (2000) (8)
“Human guinea pig” asks for animal studies (2014) (8)
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. (2002) (7)
[Naproxen (Naprosyn) and mobilization in the treatment of acute ankle sprains]. (1986) (7)
Debate on screening for breast cancer is not over (2001) (7)
The Danish National Board of Health circles the wagons (2021) (7)
Citation bias: questionable research practice or scientific misconduct? (2022) (7)
Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. (1988) (7)
Calculating the number of new generalist physicians. (1993) (7)
Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols (2019) (7)
Asthma guidelines on house dust mites are not evidence-based (2007) (7)
Overstating the Evidence for Lung Cancer Screening (2007) (7)
House dust mite control measures for asthma. (2008) (7)
Musculoskeletal disorders. Non-steroidal anti-inflammatory drugs. (2004) (7)
Screening for breast cancer with mammography. (2006) (7)
What is publication? (1988) (6)
Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review (2019) (6)
The Two-County breast screening trial cannot provide a reliable estimate of the effect of breast cancer screening. (2012) (6)
[Overview and meta-analysis]. (1988) (6)
Zidovudine dosage. Nordic Medical Research Councils' HIV Therapy Group. (1993) (6)
Reduction in mortality from breast cancer (2005) (6)
Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. (2004) (6)
General health checks for reducing morbidity and mortality from disease (2011) (6)
Redactions in protocols for drug trials: what industry sponsors concealed (2018) (6)
An unmerciful end (2001) (6)
Effect of lithium on suicide and mortality in mood disorders: A systematic review. (2019) (6)
Screening mammography: setting the record straight. Authors' reply (2002) (6)
Core belief in powerful effects of placebo interventions is in conflict with no evidence of important effects in a large systematic review (2001) (6)
The effect of fusidic acid on Tanzanian patients with AIDS. (1990) (6)
Do patients with osteoarthritis get the clinical research they need? (2000) (6)
Breast cancer: Updated screening guidelines — much ado about small improvements (2016) (6)
Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? (2013) (5)
Beyond randomized controlled trials (2002) (5)
The coronavirus pandemic: can we handle such epidemics better? (2020) (5)
Screening for breast cancer with mammography. (2009) (5)
Yield of diagnostic tests for opportunistic infections in AIDS: a survey of 33 patients. (1988) (5)
A cause for celebration, and caution (2009) (5)
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study. (1999) (5)
Coronary events with lipid-lowering therapy: The AFCAPS/TexCAPS trial [1] (multiple letters) (1999) (5)
Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies (2017) (5)
European governments should sue Roche and prescribers should boycott its drugs (2012) (5)
Depression severity and effect of antidepressant medications. (2010) (5)
Underreporting of Conflicts of Interest Among Trialists : A Cross-sectional Study (2013) (5)
Trends in breast-conserving surgery in the Southeast Netherlands: comments on article by Ernst and colleagues. Eur J Cancer 2001, 37, 2435-2440. (2002) (5)
Misleading quotations and other errors persist in rejoinder on breast cancer screening. (2004) (5)
DITIOCARB IN HIV INFECTION (1988) (5)
[Bibliometric analysis of Danish medical research 1986-1992]. (1995) (5)
A totally new system is needed for drug research and development (2018) (4)
National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. (2016) (4)
Solving the shortage of primary care physicians. (1993) (4)
Muscular adverse effects are common with statins (2014) (4)
The US Food and Drug Administration’s authorisation of Purdue’s controlled-release methylphenidate for adult ADHD: comments on the regulatory practice (2021) (4)
Financial conflicts of interest and outcomes and quality of systematic reviews (2017) (4)
More on mammography (2000) (4)
Antidepressants are addictive and increase the risk of relapse (2016) (4)
Long-term use of antipsychotics and antidepressants is not evidence-based. (2020) (4)
[Cochrane reviews compared with industry-supported and other meta-analyses of the same drugs--secondary publication]. (2006) (4)
Lack of immunomodulating effect of disulfiram on HIV positive patients. (1990) (4)
Fundamental errors in estimate of lives saved by screening (2009) (4)
Musculoskeletal disorders. Non-steroidal anti-inflammatory drugs. (2003) (4)
Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors (2018) (4)
Wampold et al.'s reiterate spin in the conclusion of a re‐analysis of placebo versus no‐treatment trials despite similar results as in original review (2007) (4)
Unbalanced reporting of benefits and harms in abstracts on rofecoxib (2010) (4)
Mammography service screening and mortality. (2003) (4)
The old man's friend. (2000) (3)
Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents (2006) (3)
Randomised clinical trials in the Scandinavian Journal of Rheumatology. (2000) (3)
Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review (2019) (3)
Screening mammography: setting the record straight (2002) (3)
Clinical inquiries. Do antibiotics improve outcomes in chronic rhinosinusitis? (2004) (3)
Thirteen years of breast screening had no measurable effect on breast cancer mortality in Norway (2013) (3)
Sponsorship of Medical Textbooks by Drug or Device Companies (2010) (3)
[Selective reporting of positive outcomes in randomised trials--secondary publication.. A comparison of protocols with published reports]. (2005) (3)
[Are relative risks and odds ratios in abstracts believable? Secondary publication]. (2006) (3)
Breast Cancer Screening in Denmark (2017) (3)
Covert duplicate publication and misleading sample size calculation: commentary on Lee et al. (2008). (2008) (3)
Screening for breast cancer. (2003) (3)
Extensive selective reporting of quality of life in clinical study reports and publications of placebo-controlled trials of antidepressants. (2020) (3)
Lead-time models produce far too low estimates of overdiagnosis with mammographic screening. (2014) (3)
ENALAPRIL, ATENOLOL, AND HYDROCHLOROTHIAZIDE IN HYPERTENSION (1986) (3)
Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications (2020) (3)
Are encasings effective in asthma caused by house dust mite allergens? (2003) (3)
Office of NHS cancer screening programme misrepresents Nordic work in breast screening row (2001) (3)
Organized mammographic screening substantially reduces breast carcinoma mortality. Authors' reply (2002) (3)
The Influence of Industry Funding and Other Financial Conflicts of Interest on the Outcomes and Quality of Systematic Reviews (2017) (3)
Double-blind trial of bestatin in HIV-positive patients. (1990) (3)
Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients. (2000) (3)
Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel study in patients with sports injuries. (1984) (3)
Routine versus selective antifungal administration for control of fungal infections in patients with cancer. (2002) (3)
Human albumin in critically ill patients. (2001) (3)
Time to halt an out of control trial with ineffective oversight (2014) (3)
EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations (2021) (3)
Beta 2-microglobulin as a prognostic marker for patients with AIDS in Dar es Salaam, Tanzania. (1990) (3)
Cross-sectional study of medical advertisements in a national general medical journal: evidence, cost, and safe use of advertised versus comparative drugs (2021) (3)
[Body lice]. (1998) (3)
Trend towards decreased survival in patients infected with HIV resistant to zidovudine. (1992) (3)
Effect of population-based screening on breast cancer mortality (2012) (3)
[Breast cancer screening--two years after]. (2002) (3)
[Placebo surgery: arthroscopic lavage and debridement of knee osteoarthritis]. (2002) (3)
Surgical treatment of morbid obesity. A survey of overall outcome 1968-1989. (1991) (2)
Author’s reply on: ‘House dust mite control measures for asthma’ (2009) (2)
UK drug regulator destroys all evidence after 15 years (2011) (2)
Comment to the editorResponse (1993) (2)
Decreased short-term production of tumor necrosis factor-alpha and interleukin-1beta in human immunodeficiency virus-seropositive subjects. (1997) (2)
Developing a new drug costs less than $100m, not $900m (2013) (2)
Anatomy of the Cochrane Review (2001) (2)
Income from reprints creates a conflict of interests (2012) (2)
Lasers and light sources for port‐wine stains (2008) (2)
[Noninferiority and equivalence randomized trials: lessons and reservations--secondary publication]. (2006) (2)
Invited response (2002) (2)
Comment on: parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren’s Syndrome (2007) (2)
AbbVie considers harms to be commercially confidential information: sign a petition (2013) (2)
Psychopharmacology Is Not Evidence-Based Medicine (2017) (2)
[What is the effect of placebo interventions? A systematic review of randomized clinical trials with placebo treated and untreated patients]. (2002) (2)
Evaluation of simple tests for detection of HIV antibodies: analysis of interobserver variation in Tanzania. (1990) (2)
Are new drugs for schizophrenia better than old ones? (2009) (2)
Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: A case study of public documents. (2021) (2)
Musculoskeletal disorders. Non-steroidal anti-inflammatory drugs. (2004) (2)
Quality of Life of Adult Patients With Attention-Deficit/Hyperactivity Disorder Taking Methylphenidate-Reply. (2016) (2)
Clinical practice should reflect clinical science. (1995) (2)
Hospital Costs for AIDS Patients (1990) (2)
Mammographic screening from age 40 years (2007) (2)
Guidelines for treatment of hypertension (1995) (2)
Screening and breast cancer. (2006) (2)
Cochrane authors on drug industry payroll should not be allowed (2019) (2)
Influence of mammography screening on use of mastectomies in Denmark (2015) (2)
Forced Medication in Psychiatry: Patients’ Rights and the Law Not Respected by Appeals Board in Denmark (2019) (2)
Update on effects of screening mammography (2002) (2)
FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials (Protocol) (2020) (2)
Authors’ reply to Lauritzen and colleagues, Newton and colleagues, and Mangin (2014) (2)
[Evidence-based surgery]. (2001) (2)
Increased incidence of cervical cancer in Sweden: an unlikely link with human papillomavirus (HPV) vaccination (2019) (2)
WITHDRAWN: Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. (2006) (2)
[The necessity of electronically updated meta-analyses: Doppler ultrasound in obstetrics as an example]. (1996) (2)
[Paracetamol has the same effect as non-steroidal anti-inflammatory agents in acute musculoskeletal injuries]. (2006) (2)
[Randomized trial and meta-analysis of somatostatin versus placebo in bleeding esophageal varices]. (1996) (2)
EMA’s mishandling of an investigation into suspected serious neurological harms of HPV vaccines (2021) (2)
Correction: Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study (2011) (2)
The patient-physician relationship: time to reimburse what we preach. (1996) (2)
Timing of data collection. (1993) (2)
Bea's Legacy (1997) (2)
The education of an educator (2001) (2)
Det informerede samtykke ved screening for brystkræft (2008) (2)
Screening for breast cancer. (2003) (2)
Study of study of changes in antidepressant use after FDA warnings is not reliable (2014) (1)
Elementary flaws in the FH01 study. (2011) (1)
Intermittent low dose prednisolone is safe in rheumatoid arthritis (1998) (1)
Somatostatin for acute oesophageal variceal bleeding (1998) (1)
Author’s reply to Tovey and colleagues (2015) (1)
[Independent clinical trials are imperative]. (2005) (1)
[General health checks and diabetes screening has no effect]. (2012) (1)
Why does the BMJ support donations of pulse oximeters when they have no effect? (2012) (1)
What are the implications of optimism bias in clinical research ? (2006) (1)
Sleep apnoea: from person to patient, and back again (2010) (1)
[Misleading report concerning our work on mammographic screening]. (2002) (1)
Shock therapy of narcolepsy (1950) (1)
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials (2023) (1)
A relationship built on mutual distrust (1994) (1)
Restoring invisible and abandoned trials: a call for people to publish the findings (2013) (1)
What is the moral collapse in the Cochrane Collaboration about? (2019) (1)
Serious harms of the COVID-19 vaccines: a systematic review (2022) (1)
Quality of Life of Adult Patients With Attention-Deficit/Hyperactivity Disorder Taking Methylphenidate. (2016) (1)
[Honest information about mammography screening, please!]. (2009) (1)
Acute cardiovascular effects of insulin in hyperglycaemic type I diabetics. (1991) (1)
Author’s reply to Dubicka and colleagues and Stone (2016) (1)
A review of randomised trials published in general high impact journals, specialist high impact journals, or specialist low impact journals (2001) (1)
Author’s reply on: ‘House dust mite control measures for asthma’ (2009) (1)
[Information about breast cancer screening presented on websites is biased and insufficient--a secondary publication]. (2005) (1)
Professional obligation. (2005) (1)
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. (2022) (1)
Suspicions of possible vaccine harms must be scrutinised openly and independently to ensure confidence (2020) (1)
Long-Term Use of Benzodiazepines, Stimulants and Lithium is Not Evidence-Based (2020) (1)
Death of a whistleblower and Cochrane’s moral collapse (2019) (1)
What do we know about the safety of the HPV vaccines? (2017) (1)
Comment on "Our prescription drugs kill us in large numbers". Author's reply. (2015) (1)
Response to Meissner: our preference of patient‐reported to observer‐reported outcomes has trivial influence on our updated systematic review of the effect of placebo (2005) (1)
Non-steroidal anti-inflammatory drugs. (2000) (1)
The background review for the USPSTF recommendation on screening for breast cancer. (2010) (1)
[There is something wrong in the studies of mammography! No support for the conclusions on benefits of breast cancer screening]. (2000) (1)
Long-term Changes in Observed Behaviour after Exposure to Psychiatric Drugs A Systematic Review of Animal Studies (2017) (1)
Mortality reduction by breast-cancer screening (2003) (1)
Patients should have free and immediate access to all information related to clinical trials (2017) (1)
Topical NSAIDs have unknown effectiveness (2008) (1)
[Mortality in breast cancer is decreasing--but not because of screening. Time to abolish the mammography screening]. (2012) (1)
Ramifications of screening for breast cancer (2006) (1)
A piece of my mind. Bea's legacy. (1997) (1)
The mammography controversy Madelon L Finkel Understandi (2005) (1)
Roche continues to drag its feet on access to Tamiflu data (2013) (1)
Undeclared motives in withdrawing a publication (2007) (1)
Procedures in Family Practice (1995) (1)
COX-2 inhibitor. (2007) (1)
[Should the population be offered general health screenings?]. (2011) (1)
Patients' views on the least acceptable increase in survival with zidovudine treatment. (1991) (1)
Review production in The Cochrane Collaboration – where is it happening and why? (2011) (1)
[Misleading about a Cochrane review on depression]. (2007) (0)
[Not Available]. (2015) (0)
[Dose-response bias]. (1986) (0)
Lessons from the mammography wars. (2010) (0)
Trials of homeopathy. (1993) (0)
[Freedom of expression and editorial independence: Four firings and a Kafkanian process]. (2008) (0)
[Is radical prostatectomy to be introduced?]. (1999) (0)
“Screening for Breast Cancer with Mammography” (2013), by Peter Gøtzsche and Karsten Jørgensen (2019) (0)
Overdiagnosis and overtreatment (2021) (0)
Are investigators’ access to trial data and rights to publish restricted and are potential trial participants informed about this? A comparison of trial protocols and informed consent materials (2021) (0)
[Attitudes of medical students to randomization or free choice in breast cancer surgery and a suggestion for a new study design]. (1989) (0)
US recommendations for women aged 40–49 years (2021) (0)
Celebrating 20 years of breast screening in the United Kingdom (2021) (0)
[Do more women lose their breast following screening--and when are we supposed to discuss it?]. (2001) (0)
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials. (2023) (0)
[Scientific articles in Ugeskrift for Laeger during a 25-year period. Types of articles and experimental design]. (1989) (0)
El acceso a los datos en la Agencia Europea del Medicamento (AEM) 1 (2011) (0)
Correction to: Cross-sectional study of medical advertisements in a national general medical journal: evidence, cost, and safe use of advertised versus comparative drugs (2021) (0)
[Overinterpretation of a non-conclusive population study on breast cancer]. (2004) (0)
Are there any differences between acupuncture and placebo acupuncture in the treatment of pain (2009) (0)
[Reply: About statistics and bias]. (2014) (0)
Authors are reluctant to respond to criticisms of their work (2017) (0)
RE: Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis (2015) (0)
The corruptive influence of easy money (2019) (0)
[Dishonesty in clinical trials is expensive for the society]. (2003) (0)
Delayed media storm in the United States after our 2001 reviews (2021) (0)
pushing children into suicide with happy pills (2019) (0)
Public access to data at drug agencies (2019) (0)
Zidovudine in HIV infection. (1993) (0)
Fraudulent celecoxib trial and other lies (2019) (0)
[Experience gained by treating Alsation dogs]. (1989) (0)
[Reference bias]. (1988) (0)
Websites on screening for breast cancer:Authors' reply (2004) (0)
Minimal clinically important differences in acute pain. Cochrane Database Syst Rev 2011;113(Suppl 3) (2011) (0)
Extraordinary exaggerations (2021) (0)
Institute for Scientific Freedom (2019) (0)
Mammographic screening for breast cancer. (2003) (0)
Tenemos demasiadas medicinas y las utilizamos demasiado (2014) (0)
The abstract was not transparent (2017) (0)
Psychiatry, the drug industry′s paradise (2019) (0)
[The Nordic Cochrane Center. Status after five years and future perspectives]. (1999) (0)
Author's response to reviews Title: Dealing with substantial heterogeneity in Cochrane reviews. Authors: (2010) (0)
Important issues in cancer screening (2021) (0)
Presentation of beneﬁts and harms of antidepressants on websites: A cross-sectional study (2020) (0)
Antibiotics as initial treatment for children with acute otitis media. Use of odds ratio in calculation of number needed to treat was inappropriate. (1997) (0)
Michael Burr management of asthma : meta-analysis House dust mite control measures in the (1998) (0)
[The rheumatologists' conflict of interest and biological medicines]. (2010) (0)
Switching cheap drugs to expensive ones in the same patients (2019) (0)
Dödligheten i bröstcancer minskar--men inte tack vare screening. Dags att slopa mammografiscreening (2012) (0)
Merck, where the patients die first (2019) (0)
Are investigators’ access to trial data and rights to publish restricted and are potential trial participants informed about this? A comparison of trial protocols and informed consent materials (2021) (0)
Long-term use of psychiatric drugs: Maudsley debate (2015) (0)
Xenotransplantation (1995) (0)
[The effects of ingestion of moderate quantities of liquorice]. (1983) (0)
Undocumented editorial on placebos (2018) (0)
Stephen Duffy's claims on the benefits and harms of breast screening are seriously wrong (2017) (0)
Authors' reply: The quality of the acupuncture interventions was considered in our systematic review (2017) (0)
[Registries and registration of clinical trials--secondary publication]. (2006) (0)
[Overdiagnosis in mammographic screening a serious problem]. (2009) (0)
What have women been told? (2021) (0)
Can screening work? (2021) (0)
[New cancer drugs are no better than old]. (2013) (0)
Anonymous authorship may reduce prescription drug deaths. (2022) (0)
LUS I SKINDPELSEN (1998) (0)
Depression Severity and Effect of Antidepressant Medications. Authors' reply (2010) (0)
Re: Et korstog mot legemiddelindustrien (2014) (0)
[Mortality following administration of human albumin]. (2001) (0)
“Screening for Breast Cancer with Mammography” (2013), by Peter (2022) (0)
Evidence-based information at invitation to breast cancer screening (2009) (0)
[Radical prostatectomy is not documented]. (1999) (0)
Were patients with unfavorable outcomes deleted in a covert duplicate publication reporting effect of placebo on hypertension? (2006) (0)
09:00 Opening presentation: Welcome to Evidence 2013 (2013) (0)
[Reply: Rosthøj misunderstands averages]. (2013) (0)
Sponsor ' s influence on conduct and reporting of industry trials : a comparison of protocols and published papers (2012) (0)
Quality assessment of mammography screening trials (2001) (0)
Long-term use of antipsychotics and antidepressants is not evidence-based. (2020) (0)
[Criticism of the Cochrane review on mammographic screening is not justified]. (2002) (0)
[Postoperative radiotherapy increases mortality in women with breast cancer diagnosed by mass screening]. (2001) (0)
Fundamental mistakes in estimate of lives saved by breast screening (2017) (0)
[Not Available]. (2015) (0)
Patientenpräferenz für subkutane im Vergleich zu intravenöser Gabe von Trastuzumab: Ergebnisse der internationalen Multicenter-Studie PrefHer (2013) (0)
abstracts: cross sectional study Believability of relative risks and odds ratios in (2006) (0)
Peter C Gøtzsche cross sectional study and harms from screening for breast cancer : Presentation on websites of possible benefits (2004) (0)
Cross-sectional study of medical advertisements in a national general medical journal: evidence, cost, and safe use of advertised versus comparative drugs (2021) (0)
Suspicions of possible vaccine harms must be scrutinised openly and independently to ensure confidence (2020) (0)
Hard sell (2019) (0)
[Hospital costs involved in the diagnosis and treatment of AIDS patients. The first 33 patients at the Royal Hospital]. (1988) (0)
Nystatin prophylaxis and treatment in severely immunodepressed patients. (2014) (0)
Stonewalling the Cochrane report on screening (2021) (0)
The drug industry is similary harmful as the tobacco industry (2013) (0)
Impotent drug regulation (2019) (0)
[When one doesn't WANT to see the evidence?]. (2010) (0)
Having the last laugh at big pharma (2019) (0)
GlaxoSmithKline and Roche won't disclose their results (2013) (0)
Screening for breast cancer. Authors' reply (2003) (0)
Restoring the two pivotal fluoxetine trials in children and adolescents with depression. (2022) (0)
The Lancet publishes the harms of screening (2021) (0)
Screening mammography and mortality (2003) (0)
Können Bisphosphonate die Prognose von Mammakarzinom-Patientinnen mit DTCs im Knochenmark verbessern? (2015) (0)
Tissue testing after breast reduction (2009) (0)
Readers respond to "the death of academic family medicine". (1995) (0)
Blood glucose was fine but the patients died (2019) (0)
[Screening for obsessive thoughts, depression and ADDH?]. (2013) (0)
systematic review of incidence trends mammography screening programmes : Overdiagnosis in publicly organised (2009) (0)
[Albumin or physiologic saline to hypovolemic intensive care patients?]. (2004) (0)
The terminology we use about medical drugs can be misleading (2023) (0)
[There is no effect of drotrecogin alfa in severe sepsis]. (2013) (0)
Paper811-14 march 1998 (1998) (0)
Very few patients benefit from the drugs they take (2019) (0)
Duodenal Ulcer. Analyses of 293 Randomized Clinical Trials. Thierry Poynard and Jean Pierre Pignon, John Libbey Eurotext, London and Paris, 1989. No. of pages: 149. Price: $30 (1990) (0)
Correction: Regular Health Checks: Cross-Sectional Survey (2012) (0)
[Randomized oxytocin trial?]. (1994) (0)
Model of outcomes of screening mammography: Information needs to support informed choices. (2005) (0)
Our findings on acupuncture are robust (2017) (0)
[The thesis about the powerless placebo]. (2004) (0)
[Randomized clinical trials in the Ugeskrift for Laeger 1948-1995]. (1997) (0)
Evidence-based medicine (2001) (0)
Acupuncture and placebo acupuncture for pain (2017) (0)
Systematic violations of patients' rights and safety: Forced medication of a cohort of 30 patients in Alaska (2020) (0)
[Importance of a wide perspective on meta-analysis. It may be of crucial significance for the patients]. (2000) (0)
Ghost authorship in evidence-based medicine (2017) (0)
SOMATOSTATIN FOR ACUTE OESOPHAGEAL VARICEAL BLEEDING. AUTHORS' REPLY (1998) (0)
Troubling results in the Lancet (2021) (0)
Confessions from an insider (2019) (0)
[Suggestion for a new case record system]. (1968) (0)
Conflicts of interest at medical journals (2019) (0)
Publication of entire Cochrane review obstructed for 5 years (2021) (0)
[Doubtful whether topically administered NSAIDs have any effect]. (2013) (0)
Data Discrepancies in Meta-analyses That Use Standarized Mean Differences—Reply (2007) (0)
VP26 Comparing Statistical Methods For Meta-Analysis Of Rare Event Data (2017) (0)
Graduate medical education confronted. (1988) (0)
Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study (2013) (0)
Follow-up Commentary (2006) (0)
Where next? (2021) (0)
A piece of my mind. The promotion. (1994) (0)
[COX-2 inhibitors and other non-steroidal anti-inflammatory agents--what is their future?]. (2006) (0)
Given the Choice (1993) (0)
Antibiotics provide only short-term relief, not long-term answers (2004) (0)
Assessment Bias in Clinical Trials (2014) (0)
The scope of practice in primary care. (2000) (0)
[Scientific articles in Ugeskrift for Laeger during a 25-year period. Analysis and interpretation of research results]. (1989) (0)
NOTICE: This document contains correspondence generated during peer review and subsequent revisions but before transmittal to production for composition and copyediting: (2019) (0)
A mere fifteen minutes. (2001) (0)
An all-too-familiar syndrome [1] (1999) (0)
The proposed review will not be independent without NICE (2011) (0)
My Living Will (1996) (0)
A piece of my mind. Given the choice. (1993) (0)
On the day that hairy died. (2002) (0)
Informed consent. (1988) (0)
Screening for Alcoholism (1988) (0)
An ACO View on Medicaid Reform (2015) (0)
The Deprofessionalization of Medicine (1988) (0)
Falsehoods and perceived censorship in Sweden (2021) (0)
Curing cancer takes more than medicine. (1997) (0)
Dr. Aesop. (1994) (0)
A feel for the water. (1995) (0)
A piece of my mind. My living will. (1996) (0)
Acupuncture for pain: our result is robust to trial selection, and our threshold for minimal clinically effect is low (2017) (0)
Generalists should teach, but who will pay? (1995) (0)
When diagnosis becomes unaffordable. (2005) (0)
Generalsystem failure calls for a revolution (2019) (0)
Screening for prostate cancer. (1996) (0)
Mammography Screening (2021) (0)
FEEDING EACH OTHER (1997) (0)
Medicinal marijuana? [1] (multiple letters) (1997) (0)
[Reliability of controlled clinical trials--the problem of randomization]. (1995) (0)
Musculoskeletal disorders. Non-steroidal anti-inflammatory drugs. (2004) (0)
[Was the zone therapy trial randomized?]. (1999) (0)
Mammography screening increases non-breast cancer mortality (2013) (0)
Hepatitis and vitamin K (1950) (0)
[Transparency, reliability and conflict of interest]. (2011) (0)
Clinical trials, abroken social contract with patients (2019) (0)
Mammography screening hasn’t lived up to expectations (2018) (0)
Editorial misconduct in the European Journal of Cancer (2021) (0)
Made in China: the coronavirus that killed millions of people. (2021) (0)
[Not Available]. (2015) (0)
[Knowledge of experts or evaluation of medical technology?]. (1996) (0)
Does screening work in Sweden? (2021) (0)
Other observational studies of breast cancer mortality (2021) (0)
Outcomes of screening mammography: information to support informed choices (2018) (0)
No visible effect of mammography screening in Denmark (2017) (0)
Total mortality should be the primary outcome in cancer screening trials (2011) (0)
Neurontin, an epilepsy drug for everything (2019) (0)
[Dubious documentation of the effect of acupuncture]. (2006) (0)
Effect of DTP Vaccines on Mortality in Children in Low-Income Countries (2019) (0)
ABSTRACTS 1st AUGUST CONFERENCE AARHUS UNIVERSITY GROUP FOR UNDERSTANDING SYSTEMATIC REVIEWS AND METAANALYSES IN TRANSLATIONAL PRECLINICAL SCIENCE November 17th 2015 Aarhus, Denmark (2016) (0)
[Not Available]. (2015) (0)
[P-pills do not cause breast cancer]. (1992) (0)
[Non-useful cancer survival statistics following the Danish Cancer Control Plan]. (2008) (0)
Intimidation, threats and violence to protect sales (2019) (0)
Where is screening at today? (2021) (0)
Authors reply: Wald et al.'s estimate of the effect of breast screening is about 10 times higher than the most reliable evidence shows (2018) (0)
[Reply to the debate on "Do women unnecessarily lose the breast following breast cancer screening?"]. (2003) (0)
US and Swedish 2002 meta-analyses (2021) (0)
RE: RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data (2011) (0)
[Misleading by the Danish Cancer Society about mammography screening]. (2013) (0)
[Our research on the pharmaceutical industry is well documented]. (2013) (0)
[Wide perspective on meta-analysis is of crucial significance for the patient]. (2000) (0)
[Evaluation of clinical trials]. (1986) (0)
[What is the relation between randomized trials and evidence-based medicine?]. (1999) (0)
What have antidepressants been tested for? A systematic review. (2020) (0)
[A wide perspective on meta-analysis--may be of crucial significance for the patients]. (2000) (0)
[Significance of Cochrane collaboration for evidence-based medicine]. (2000) (0)
Where is the effect of mammography screening (2017) (0)
Organised crime, the business model of big pharma (2019) (0)
What do thousands of doctors on industry payroll do? (2019) (0)
Busting the industry myths (2019) (0)
[Survival of patients with zidovudine resistant HIV]. (1994) (0)
[Should the announcement of scientific dishonesty be revised yet again?]. (2013) (0)
Zidovudine in HIV infection (1991) (0)
Harms dismissed by the Cochrane Breast Cancer Group (2021) (0)
Estimate of harm/benefit ratio of mammography screening was five times too optimistic (2020) (0)
[Are invitations to mammography screening a reasonable basis for informed consent?-- Secondary publication]. (2006) (0)
Scientific debates in the United States (2021) (0)
Author's reply (1996) (0)
Tabár threatens the BMJ with litigation (2021) (0)
Why mammography screening has not lived up to expectations from the randomised trials (2011) (0)
[Non-evidence based comment on the benefit of mattress encasings in asthma with house dust mite allergy]. (2003) (0)
The proposed review of breast screening will not be independent without NICE (2017) (0)
Cimetidine and weight loss (1993) (0)
Sponsors' influence on reporting of results in industry-sponsored trials: a comparison of protocols and published papers. Cochrane Database Syst Rev 2011;127(Suppl 3) (2011) (0)
Standardised mean difference in meta analyses-How reliable is it in practice ? (2010) (0)
[Cooperation on systematic analysis of treatment effects]. (1994) (0)
Statistical questions in evidence-based medicine. Martin Bland and Janet Peacock, Oxford University Press, Oxford, 2000. No. of pages: 251. Price: £19.95. ISBN 0-19-262992-1 (2003) (0)
Review : Somatostatin analogues reduce blood products used in acute bleeding esophageal varices but do not reduce mortality (2004) (0)
Probability Without Equations – Concepts For Clinicians. Bart K. Holland, Johns Hopkins University Press, 1998. No. of pages: 113. Price: $20.50 (paperback) $54.00 (hardcover). ISBN 0‐8018‐5759‐7 (1999) (0)
[Wrong statement on natural medicine]. (1991) (0)
Dose-response relationship of extended-release methylphenidate for ADHD in adults: post-hoc analysis based on a systematic review (2021) (0)
[Control should be counteracted]. (2011) (0)
Nonsteroidal anti-inflammatory drugs vs paracetamol for rheumatoid arthritis (2001) (0)
Correction to: Cross-sectional study of medical advertisements in a national general medical journal: evidence, cost, and safe use of advertised versus comparative drugs (2021) (0)
Estimate of breast screening benefit was 6 times too large (2017) (0)
[Insufficient access to research data not acceptable]. (2010) (0)
[The scientific basis for the assessment of medical technology]. (1996) (0)
Tabár's ‘beyond reason' studies (2021) (0)
Incorrect statements by Novo Nordisk (2013) (0)
[The expert knowledge or the assessment of medical technology II?]. (1996) (0)
acupuncture groups acupuncture, placebo acupuncture, and no review of randomised clinical trials with Acupuncture treatment for pain: systematic (2009) (0)
[Meta-analysis of magnesium therapy in myocardial infarction]. (1995) (0)
Questionable research and marketing of a combination drug for smoker’s lungs (2014) (0)
[Treatment of patients and safety--significance of the Cochrane databases]. (1995) (0)
Ad hominem attacks: a measure of desperation? (2021) (0)
The Cost of CIN Detection in Cervical Screening : The Impact of a Definition of a Positive Screening Test (2010) (0)
Somatostatin in bleeding oesophageal varices (1996) (0)

This paper list is powered by the following services:

Other Resources About Peter C. Gøtzsche

What Schools Are Affiliated With Peter C. Gøtzsche?

Peter C. Gøtzsche is affiliated with the following schools:

Peter C. Gøtzsche's Academic­Influence.com Rankings